MonicaSThakarMD

Pediatric Hematology & Oncology • Seattle, WA

Professor, Pediatrics, Fred Hutchinson Cancer Center and University of Washington

Join to view full profile

Dr. Thakar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Thakar's full profile

Already have an account?

Office
1100 Fairview Ave N D5-280
Seattle, WA 98109

Education & Training

University of WashingtonFellowship, Pediatric Hematology/Oncology, 2004 - 2007
University of ChicagoResidency, Pediatrics, 2001 - 2004
Medical University of South CarolinaClass of 2001

Certifications & Licensure

WA State Medical License 2004 - 2026
WI State Medical License 2010 - 2019
IL State Medical License 2001 - 2004
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia Start of enrollment: 2007 Feb 01
Completed
Phase 2
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders Start of enrollment: 2006 Jun 01
Completed
Phase 2
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 1, Phase 2
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2009 May 01
Completed
Natural History Study of SCID Disorders Start of enrollment: 2010 Sep 02
Enrolling by invitation
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 Start of enrollment: 2014 Feb 02
Completed
Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995 Start of enrollment: 2014 Jun 01
Enrolling by invitation
Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Start of enrollment: 2013 Mar 20
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

The Impact of Pretransplant Respiratory Virus Detection on Posttransplant Outcomes in Children Undergoing Hematopoietic Cell Transplantation.
Sara Ruth Kim, Anna Nordlander, Hu Xie, Yae-Jean Kim, Chikara Ogimi
Clinical Infectious Diseases. 2024-09-26
Outcomes of patients undergoing third hematopoietic cell transplantation for hematologic malignancies.
Emily R Cox, Corinne Summers, Filippo Milano, Ann Dahlberg, Marie Bleakley
Annals of Hematology. 2024-09-01
2 citations
Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study.
Hesham Eissa, Monica S Thakar, Ami J Shah, Brent R Logan, Linda M Griffith
The Journal of Allergy and Clinical Immunology. 2024-01-01

Abstracts/Posters

Comparison of Outcomes between HSCT Donor Sources for Pediatric Patients with Hematologic Malignancies
Monica Thakar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019